| Assay ID | Title | Year | Journal | Article |
|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID517037 | Antiinflammatory activity in Sprague-Dawley rat assessed as reduction in carrageenan-induced inflammatory pain at 10 uL, intraplanter | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
| 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. |
| AID756114 | Cytotoxicity against human HepG2 cells by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID517035 | Lipophilicity, log P of the compound | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
| 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. |
| AID756112 | Antiproliferative activity against HUVEC after 72 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1186234 | Tmax in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. |
| AID756127 | Inhibition of human recombinant soluble epoxide hydrolase assessed as cyano(6-methoxy-naphthalen-2-yl)methyl trans-[(3-phenyloxyran-2-yl)methyl] carbonate conversion to 6-methoxy-2-naphthaldehyde preincubated for 5 mins prior to substrate addition by fluo | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID1186232 | Cmax in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. |
| AID756116 | Inhibition of full length recombinant c-RAF (unknown origin) using MEK1 as substrate after 1 hr by luminescence assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID756113 | Cytotoxicity against human HuH7 cells by MTT assay | 2013 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
| Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors. |
| AID517036 | Inhibition of human recombinant soluble epoxide hydrolase by fluorescence assay | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
| 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. |
| AID517038 | Inhibition of mouse recombinant soluble epoxide hydrolase by fluorescence assay | 2010 | Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
| 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. |
| AID1186231 | AUC in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. |
| AID1186233 | Half life in Swiss Webster mouse at 0.3 mg/kg, po administered as cassette dosing | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. |
| AID1186230 | Inhibition of human recombinant soluble epoxide hydrolase assessed as half-life of enzyme-inhibitor complex by FRET-based ACPU displacement assay | 2014 | Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
| Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. |
| AID1798579 | Mtb EHB Inhibition Assay from Article 10.1016/j.jmb.2008.06.030: \\The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.\\ | 2008 | Journal of molecular biology, Sep-12, Volume: 381, Issue:4
| The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |